Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant.

Kye Ling Wong, Tze Wei Chan, Chieh Hwee Ang, Tertius Tuy, Hein Than, Melinda Si Yun Tan, Lawrence Ng, Shin Ong, Yunxin Chen, Francesca Lim, Chandramouli Nagarajan, William Hwang, Yeow Tee Goh, Yeh-Ching Linn, Aloysius Ho, Jeffrey Quek

Blood (2025) 146 (Supplement 1): 5982.

https://doi.org/10.1182/blood-2025-5982

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy

Guilherme Perini, Ahmad Alhuraiji, Mary Ann Anderson, Gilberto Israel Barranco Lampón, Otavio Cesar Carvalho Guimarães Baiocchi, Ahmet Emre Eskazan, Yeow Tee Goh, Wei-Han Huang, Mervat Mattar, Evgeny Nikitin, Stephen Opat, Miguel Pavlovsky, Wei Xu

Blood (2025) 146 (Supplement 1): 7937.

https://doi.org/10.1182/blood-2025-7937

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab - Real-World Retrospective Study

Blood (2024) 144 (Supplement 1): 6277.

https://doi.org/10.1182/blood-2024-193417

Published: 2024

Journal Articles

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2024-200952

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore

Blood (2024) 144 (Supplement 1): 6467.

https://doi.org/10.1182/blood-2024-205120

Published: 2024

Journal Articles

The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

Jing Yuan Tan, Jason Yongsheng Chan, Shin Yeu Ong, Chandramouli Nagarajan, Yunxin Chen, Francesca Lorraine Wei Inng Lim, Nicholas Francis Grigoropoulos, Ya Hwee Tan, Joshua Tian Ming Hoe, Jianbang Chiang, Esther Chang, Eileen Poon, Nagavalli Somasundaram, Miriam Tao, Yeow Tee Goh, Soon Thye Lim, Lawrence Cheng Kiat Ng

Blood (2024) 144 (Supplement 1): 6450.

https://doi.org/10.1182/blood-2024-194684

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Chandramouli Nagarajan, Melinda Tan, Yunxin Chen, Melissa Ooi, Sanjay De Mel, Allison Tso, Lawrence Ng, Hein Than, Yeow Tee Goh, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 6721.

https://doi.org/10.1182/blood-2023-173476

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Blood (2023) 142 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2023-184423

Published: 2023

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Morag Griffin, Richard Kelly, Dries Deeren, Yeow Tee Goh, Eric Tse, Kensuke Usuki, Raymond Wong, Regina Horneff, Lisa Tan, Michael Yeh, Jessica Savage, Jeff Szer

Blood (2022) 140 (Supplement 1): 2937–2939.

https://doi.org/10.1182/blood-2022-163117

Published: 2022

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Kiat Hoe Ong

Blood (2022) 140 (Supplement 1): 12596–12597.

https://doi.org/10.1182/blood-2022-157940

Published: 2022

Journal Articles

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

Raymond S Wong, Juan Ramon Navarro, Narcisa Sonia Comia, Yeow Tee Goh, Henry Idrobo, Daolada Kongkabpan, David Gomez-Almaguer, Mohammed Al-Adhami, Temitayo Ajayi, Paulo Alvarenga, Pascal Deschatelets, Cedric Francois, Federico Grossi, Teresita Dumagay

Blood (2021) 138 (Supplement 1): 606.

https://doi.org/10.1182/blood-2021-147493

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant.

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab - Real-World Retrospective Study

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore

The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only